Vanda Pharmaceuticals (VNDA) Net Equity Issued and Repurchased (2013 - 2018)

Vanda Pharmaceuticals (VNDA) reported Net Equity Issued and Repurchased of -$30000.0 for Q2 2018, down 100.03% sequentially from $100.9 million in Q1 2018.

Vanda Pharmaceuticals (VNDA) Net Equity Issued and Repurchased (2013 - 2018) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 3 years of Net Equity Issued and Repurchased data on file, last reported at -$30000.0 in Q2 2018.

  • For the quarter ending Q2 2018, Net Equity Issued and Repurchased changed N/A year-over-year to -$30000.0; the trailing twelve-month figure through Mar 2019 stood at -$30000.0 (down 100.02% YoY), and the FY2018 full-year result was $100.9 million, changed N/A from the prior year.
  • Net Equity Issued and Repurchased declined to -$30000.0 in Q2 2018, from $100.9 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $100.9 million in Q1 2018 to a low of -$30000.0 in Q2 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Vanda Pharmaceuticals 318.71 Mn 116.40 Mn 48.56 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2018 -30,000.00
Jun 30, 2018 -30,000.00
Mar 31, 2018 100.90 Mn
Mar 31, 2018 100.90 Mn
Dec 31, 2014 25.00 Mn
Dec 31, 2014 25.00 Mn
Dec 31, 2013 -47,000.00
Dec 31, 2013 -47,000.00